When added to optimized oral anti-lipid therapy, a PCSK9 blocker provided an additional 25% risk reduction in a first cardiovascular event, new data show.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/global-trial-pcsk9-inhibitor-provides-major-protection-2025a1000uzp?src=rss
Author :
Publish date : 2025-11-09 17:00:00
Copyright for syndicated content belongs to the linked Source.
